Working… Menu

CardioMEMS HF System OUS Post Market Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02954341
Recruitment Status : Recruiting
First Posted : November 3, 2016
Last Update Posted : January 8, 2021
Information provided by (Responsible Party):
Abbott Medical Devices

Brief Summary:
The purpose of this Post Market Study (PMS) is to evaluate the use of the CardioMEMS HF System in patients with Class III Heart Failure in a commercial setting.

Condition or disease Intervention/treatment
Heart Failure Left-Sided Heart Failure Congestive Heart Failure Device: CardioMEMS HF System

Layout table for study information
Study Type : Observational
Estimated Enrollment : 800 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: CardioMEMS HF System OUS Post Market Study
Actual Study Start Date : July 2016
Estimated Primary Completion Date : July 2023
Estimated Study Completion Date : December 2023

Primary Outcome Measures :
  1. Freedom from device/system related complications [ Time Frame: Two year ]
  2. Freedom from pressure sensor failure. [ Time Frame: Two year ]
  3. Annualized HF hospitalization rate at 1 year compared to the HF hospitalization rate in the year prior to enrollment. [ Time Frame: One year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adults with New York Heart Association (NYHA) Class III Heart Failure (HF) who have experienced a heart failure hospitalization within the past 12 months.

Inclusion Criteria:

  1. Written informed consent obtained from subject
  2. ≥ 18 years of age
  3. Diagnosis of NYHA Class III Heart Failure
  4. At least 1 HF hospitalization within 12 months of Baseline visit
  5. Subjects with reduced LVEF heart failure should be receiving a beta blocker for 3 months and an ACE-I or ARB for one month unless in the investigator's opinion, the subject is intolerant to beta blockers, ACE-I or ARB.
  6. Subjects with a BMI ≤ 35. Subjects with BMI >35 will require their chest circumference to be measured at the axillary level, if > 65 inches the patient will not be eligible for the study.
  7. Subjects with pulmonary artery branch diameter ≥ 7mm - (implant target artery - assessed during the RHC)
  8. Subjects willing and able to comply with the follow-up requirements of the study

Exclusion Criteria:

  1. Subjects with an active infection
  2. Subjects with history of recurrent (> 1) pulmonary embolism or deep vein thrombosis
  3. Subjects who, in the Investigator's opinion, are unable to tolerate a right heart catheterization
  4. Subjects who have had a major cardiovascular event (e.g., myocardial infarction, open heart surgery, stroke, etc.) within 2 months of Baseline Visit
  5. Subjects with Cardiac Resynchronization Device (CRT) implanted < 3 months prior to enrollment
  6. Subjects with a Glomerular Filtration Rate (GFR) < 25 ml/min (obtained within 2 weeks of the baseline visit) who are non-responsive to diuretic therapy or who are on chronic renal dialysis
  7. Subjects with congenital heart disease or mechanical right heart valve(s)
  8. Subjects likely to undergo heart transplantation or VAD within 6 months of baseline visit
  9. Subjects with known coagulation disorders
  10. Subjects with a hypersensitivity or allergy to aspirin, and/or clopidogrel (not applicable for subjects taking anti-coagulation therapy or other approved anti-platelets therapy).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02954341

Layout table for location contacts
Contact: Maxime De Groof
Contact: Poornima Sood

Layout table for location information
Australia, Queensland
The Prince Charles Hospital Active, not recruiting
Chermside, Queensland, Australia, 4032
CHR Citadelle Recruiting
Liège, Belgium
Contact: Pierre Troisfontaines, MD         
Rigshospitalet Recruiting
Copenhagen, Denmark
Contact: Kasper Rossing, MD         
CHRU de Lille Active, not recruiting
Lille, France
United Kingdom
Royal Bromptom Hospital Active, not recruiting
London, United Kingdom
Sponsors and Collaborators
Abbott Medical Devices
Layout table for investigator information
Study Chair: Martin R Cowie, MD Royal Brompton & Harefield NHS Foundation Trust
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Abbott Medical Devices Identifier: NCT02954341    
Other Study ID Numbers: SJM-CIP-10147
First Posted: November 3, 2016    Key Record Dates
Last Update Posted: January 8, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases